# Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma

> **NCT03697655** · PHASE2 · UNKNOWN · sponsor: **Polish Myeloma Consortium** · enrollment: 274 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Daratumumab 20 MG/ML [Darzalex]

## Key facts

- **NCT ID:** NCT03697655
- **Lead sponsor:** Polish Myeloma Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-10
- **Primary completion:** 2020-09
- **Final completion:** 2024-07
- **Target enrollment:** 274 (ESTIMATED)
- **Last updated:** 2019-01-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03697655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03697655, "Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03697655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*